 BOSTON, Oct. 17, 2022 GLOBE NEWSWIRE -- Galecto, Inc. NASDAQ: GLTO, a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a live conference call and webcast at 8:00 am ET on Tuesday, November 8, 2022 to review topline data from the Companys Phase 1b2a GULLIVER-2 trial for liver cirrhosis. 